Barriers to Care in Gout: From Prescriber to XXXX .

@entity1 @entity210 @entity285 @entity414
OBJECTIVE: To explore the understanding of @entity210 and its management by @entity1 and general practitioners (GP), and to identify barriers to optimal @entity210 care. METHODS: Semistructured interviews were conducted with 15 GP and 22 @entity1 in Sydney, Australia. Discussions were focused on medication adherence, experiences with @entity210 , and education and perceptions around interventions for @entity210 . Interviews were audio recorded, transcribed verbatim, and analyzed for themes using an analytical framework. RESULTS: Adherence to urate-lowering medications was identified as problematic by GP, but less so by @entity1 with @entity210 . However, @entity1 had little appreciation of the risk of acute attacks related to variable adherence. @entity1 felt stigmatized that their @entity210 diagnosis was predominantly related to perceptions that @entity285 and dietary excess were causal. @entity1 felt they did not have enough education about @entity210 and how to manage it. A manifestation of this was that @entity414 concentrations were infrequently measured. GP were concerned that they did not know enough about managing @entity210 and most were not familiar with current guidelines for management. For example and importantly, the strategies for reducing the risk of acute attacks when commencing urate-lowering therapy (ULT) were not well appreciated by GP or @entity1 . CONCLUSION: @entity1 and GP wished to know more about @entity210 and its management. Greater success in establishing and maintaining ULT will require further and better education to substantially benefit @entity1 . Also, given the prevalence, and personal and societal significance of @entity210 , innovative approaches to transforming the management of this eminently treatable disease are needed.
